Physical activity does not alter prolactin levels in post-menopausal women: results from a dose-response randomized controlled trial

Darren R. Brenner1,2,3*, Yibing Ruan1, Andria R. Morielli4, Kerry S. Courneya4 and Christine M. Friedenreich1,2,3

Abstract
Background: Increased circulating levels of prolactin have been associated with increased risk of both in situ and invasive breast cancer. We investigated whether or not physical activity had a dose–response effect in lowering plasma levels of prolactin in postmenopausal women.

Methods: Four hundred previously inactive but healthy postmenopausal women aged 50–74 years of age were randomized to 150 or 300 min per week of aerobic physical activity in a year-long intervention. Prolactin was measured from fasting samples with a custom-plex multiplex assay.

Results: A high compared to moderate volume of physical activity did not reduce plasma prolactin levels in intention-to-treat (Treatment Effect Ratio (TER) 1.00, 95% Confidence Interval (CI) 0.95 – 1.06) or per-protocol analyses (TER 1.02, 95% CI 0.93 – 1.13).

Conclusions: It is unlikely that changes in prolactin levels mediate the reduced risk of breast cancer development in post-menopausal women associated with increased levels of physical activity.

Trial registration: clinicaltrials.gov identifier: NCT01435005.

Keywords: Physical Activity, Randomized Controlled Trial, Breast Cancer, Prolactin

Introduction
The primary hypothesized mechanisms underlying the associations between physical activity and reduced breast cancer include reductions in adiposity, sex hormone levels, insulin resistance and chronic inflammation [1]. These pathways only explain some portion of the association and additional mechanisms require identification and further investigation.

Prolactin is a luteotropic peptide hormone involved in regular lactation which is produced by the anterior pituitary gland. Increased circulating levels of prolactin have been associated with increased risk of both in situ and invasive breast cancer [2]. Two previous exercise intervention trials in post-menopausal women did not observe changes in prolactin levels in response to moderate physical activity [3, 4] compared to controls. As part of the Breast cancer and Exercise Trial in Alberta (BETA) we investigated: 1) the effects of increased levels of moderate to vigorous physical activity (MVPA) on levels of prolactin and 2) whether a higher level of activity led to larger changes in prolactin levels.

Materials and methods
The design of the BETA study has been previously described in detail [5]. Briefly, 400 previously inactive but otherwise healthy postmenopausal women of age were randomized to 150 (MODERATE) or 300 (HIGH) minutes per week of aerobic physical activity for a year-long intervention. Women were eligible for randomization if they were between 50–74 years of age, with no previous diagnosis of invasive cancer, no major comorbidities,

* Correspondence: Darren.Brenner@albertahealthservices.ca
1Department of Cancer Epidemiology and Prevention Research, CancerControl Alberta, Alberta Health Services, Holy Cross Centre, Room 513C, Box ACB, 2210 - 2nd St. SW, Calgary, AB T2S 3C3, Canada
2Department of Oncology, Cumming School of Medicine University of Calgary, Calgary, AB, Canada
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
obtained physical approval for participation, had a body mass index of 22–40, were moderately sedentary, not a current smoker or excessive drinker, not currently on a weight loss program, English speaking and not planning to be out of the study site areas for more than 4 consecutive weeks during the subsequent 18 months. Both intervention arms were prescribed the same frequency (five days/week) and intensity (moderate-to-vigorous) of aerobic exercise. The training targets were 60 minutes/session (300 total minutes/week) for the HIGH group, and 30 minutes/session (150 total minutes/week) for the MODERATE group. Wrist-worn heart rate were given to each participant and used to ensure a 65–75% maximum heart rate reserve (HRR) was being achieved during each exercise session. A ramp-up period was included where the intensity, frequency and duration of exercise were gradually increased during the first three months of the intervention until the target exercise prescriptions were attained. Fasting blood samples were collected from all participants at baseline, 6 and 12 months following a 24 h abstinence from alcohol intake and exercise and at least 10 h after their last meal. Prolactin levels in plasma were measured with a customplex multiplex assay (Eve Technologies, Calgary, AB, Canada), using the Bio-Plex™ 200 system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The assay sensitivity for prolactin was 30.2 pg/ml and the inter-assay coefficient of variation was 5.5%. Samples for each participant at different time points were all analyzed in the same batch and each batch included an equal number of MODERATE and HIGH blood samples.

Predicted VO$_2$ max was estimated from a modified Balke treadmill test [6] using the multistage model and the American College of Sports Medicine metabolic equations for estimating maximum oxygen consumption [7]. Body composition was estimated from full body dual energy X-ray absorptiometry (DXA) scans to assess overall percent body fat and total fat mass. Computed tomography (CT) scans were taken at the level of the umbilicus to measure subcutaneous and intra-abdominal adiposity.

We considered the comparison of means of 12-month outcomes (log transformed, with no adjustment for baseline values) for the prolactin outcomes. Standard deviation was estimated from previous reports [8]. A sample size of 200 participants per group provided 90% power to detect anticipated changes of 4% between the treatment groups at $\alpha = 0.05$. Prolactin changes in the two arms were compared in both intention-to-treat and per-protocol analysis using linear mixed models as previously described, adjusting for baseline prolactin levels [9]. A per-protocol analysis was conducted on participants achieving ≥60% of prescribed exercise duration in their target heart rate zone. To investigate whether the effects of exercise were restricted to particular subgroups, stratified analyses were conducted on a priori variables including baseline body mass index (BMI (kg)/height (m$^2$)), estimated physical fitness (VO$_{2\text{max}}$), and total percent body fat.

The study protocol was approved by the Alberta Cancer Research Ethics Committee and the Conjoint Health Research Ethics Board of the University of Calgary and the Health Research Ethics Board of the University of Alberta. All participants provided written informed consent.

**Results**

The distribution of the study participants’ baseline characteristics was similar in the two trial arms with no meaningful differences between arms [9]. Baseline prolactin levels were 10565 (SD = 6963) pg/ml in MODERATE

Table 1 Intention-to-treat and per-protocol analyses of prolactin concentrations between high and moderate volume exercise groups in BETA, (n = 386)

| Group    | n  | Baseline Geometric Mean$^a$ | 95% CI | 6 Months Geometric Mean | 95% CI | 12 Months Geometric Mean | 95% CI | Treatment effect | Between-group $P^c$ |
|----------|----|-----------------------------|-------|-------------------------|-------|--------------------------|-------|------------------|-------------------|
| Intention-to-treat | | | | | | | | | |
| High     | 195| 9368                        | 8720 – 10064 | 9353 | 8741–10008 | 9035 | 8467 – 9641 | 1.00 | 0.95 – 1.06 |
| Moderate | 191| 9331                        | 8713 – 9992 | 9230 | 8644–9855 | 9017 | 8457 – 9613 | 0.90 |
| Per-protocol$^d$ | | | | | | | | | |
| High     | 80 | 8761                        | 8002 – 9591 | 9158 | 8225–10198 | 8700 | 7904 – 9576 | 1.02 | 0.93 – 1.13 |
| Moderate | 58 | 9653                        | 8284 – 11248 | 9251 | 8110–10551 | 9366 | 8275 – 10600 | 0.62 |

$^a$Geometric mean of prolactin was in the unit of pg/ml

$^b$The geometric mean ratios were estimated from least square means for the difference in treatment effect between high and moderate volume exercisers averaged across the entire study period adjusted for the baseline values and then back log-transformed

$^c$P value corresponds to the null hypothesis that the ratio of treatment effect between high- and moderate-volume groups equals 1 against the 2-sided alternative hypothesis

$^d$Women assigned to the moderate-volume group were adherent if they completed 90% to 100% of the exercise prescription (mean, 135–150 min/week), weeks 13 to 52 at full prescription; women assigned to the high-volume group were adherent if they completed at least 90% of the exercise prescription (mean, ≥270 min/week), weeks 13 to 52 at full prescription.
Table 2: Stratified analyses of changes in prolactin between high volume and moderate volume exercise groups in BETA, 2010–2013 (n = 386)

| Stratification variables | Prescribed exercise duration | n   | 6 months percent change from baseline | 12 months percent change from baseline | Treatment effect<sup>a</sup> | Between-group P<sup>b</sup> |
|--------------------------|-----------------------------|-----|--------------------------------------|---------------------------------------|-----------------------------|-----------------------------|
|                          |                             |     |                                      |                                       | Ratio of HIGH:MOD          | 95% CI          |                              |
| Time at high intensity<sup>c</sup> |                             |     |                                      |                                       |                            |                |
| <60% prescribed          | MODERATE                    | 17  | −2.0                                 | −6.4                                  | 1.06                        | 0.93 – 1.21     | 0.40                      |
|                          | HIGH                        | 44  | 8.0                                  | 0.3                                   |                            |                |
| ≥60% prescribed          | MODERATE                    | 41  | −5.1                                 | −1.5                                  | 1.01                        | 0.88 – 1.17     | 0.85                      |
|                          | HIGH                        | 36  | 0.5                                  | −1.2                                  |                            |                |
| BMI<sup>d</sup>          | < 30                        | MODERATE | 116 | 15.1                                 | 16.0                                  | 0.98                        | 0.91, 1.06     | 0.59                      |
|                          | HIGH                        | 121 | −4.7                                 | −4.7                                  |                            |                |
| ≥ 30                     | MODERATE                    | 75  | 11.3                                 | 3.6                                   | 1.05                        | 0.95, 1.15     | 0.36                      |
|                          | HIGH                        | 74  | 7.7                                  | −1.6                                  |                            |                |
| VO₂max level<sup>e</sup> | < 27.2 ml/kg min            | MODERATE | 93  | 12.7                                 | 2.5                                   | 1.04                        | 0.96, 1.13     | 0.38                      |
|                          | HIGH                        | 98  | 3.7                                  | −2.2                                  |                            |                |
| ≥ 27.2 ml/kg min         | MODERATE                    | 98  | 14.4                                 | 19.8                                  | 0.98                        | 0.90, 1.06     | 0.57                      |
|                          | HIGH                        | 97  | −3.9                                 | −5.0                                  |                            |                |
| Total body fat<sup>f</sup> | < 29.7 kg                  | MODERATE | 94  | 9.1                                  | 8.9                                   | 0.98                        | 0.90, 1.07     | 0.61                      |
|                          | HIGH                        | 99  | −4.7                                 | −3.8                                  |                            |                |
| ≥ 29.7 kg                | MODERATE                    | 97  | 18.1                                 | 13.0                                  | 1.03                        | 0.95, 1.12     | 0.48                      |
|                          | HIGH                        | 96  | 4.7                                  | −3.3                                  |                            |                |

<sup>a</sup>High:Moderate ratio of geometric means for prolactin levels over 12 months adjusted for prolactin level at baseline. A ratio <1.0 indicates lower prolactin concentrations in the HIGH exercise group at 6 and 12 months; a ratio >1.0 indicates lower prolactin concentrations in the MODERATE exercise group; a ratio equal to 1.0 indicates no difference in prolactin concentrations between the HIGH and MODERATE exercise groups

<sup>b</sup>P for testing the HIGH-MODERATE group difference over 12 months from the linear mixed model, adjusted for prolactin level at baseline

<sup>c</sup>Included n = 138 women for whom, across weeks 13–52 (at full prescription), average adherence in the exercise logs was 90–100% in the MODERATE group (135–150 min/week; n = 58) or ≥90% in the HIGH group (≥270 min/week; n = 80). Time at high intensity was defined as time exercising at an intensity of 60–80% heart rate reserve averaged for each participant over 52 weeks. Cut points for the stratified analysis were 60% of the prescribed durations, i.e., 90 min/week in the MODERATE group and 180 min/week in the HIGH group

<sup>d</sup>Body mass index at baseline

<sup>e</sup>Cut point of the baseline VO₂max level for the stratified analysis were the median value for all study participants (MODERATE and HIGH group)

<sup>f</sup>Cut point of the baseline total body fat level for the stratified analysis were the median value for all study participants (MODERATE and HIGH group)
ratios in any of the subgroups were significantly different in percent body fat did not mediate the intervention effect. In the study by Tworoger et al. [3], change by Reding et al. [4], baseline BMI did not alter the treat-
ment effect. In the study of exercise per day, was considered [3, 4]. In the study
larly, the results from these previous trials remained un-
have reported null effects on prolactin levels [3, 4]. Simi-
larly, the results from these previous trials remained un-
changed when exercise adherence, measured as minutes of exercise per day, was considered [3, 4]. In the study
by Reding et al. [4], baseline BMI did not alter the treatment
impact. In the study by Tworoger et al. [3], change in percent body fat did not mediate the intervention effect however, women in the exercise group who increased their VO_2max by >5% had a statistically significant reduction in prolactin levels.

Our analyses were motivated by the strong animal and in vitro data supporting an important role of prolactin in breast carcinogenesis [10] and epidemiologic data sug-
gesting an association of increased levels with breast cancer risk [11]. While our study did not observe significant impacts of exercise on levels of prolactin, it is worth noting that there are complex relationships between ex-
ercise and prolactin levels which may explain our null
findings. For example, threshold effects of exercise in-
tensity have been observed in the literature [12], which suggests that the intensity of exercise in the BETA trial may not have been high enough despite a target >65%
HRR. Furthermore, effects may differ by age as there are several studies among young athletic populations where increased levels of prolactin are reported post-acute
bouts of exercise [12–14], while effects among older sedentary populations are less well characterized.

In conclusion, the results from the BETA study suggest that 300 min per week of moderate-intensity aerobic exercise does not reduce prolactin levels more than 150 min per week in a year-long intervention in postmenopausal women. It is unlikely that changes in prolactin levels mediate the reduced risk of breast cancer development in post-menopausal women associated with increased physical activity at any level.

Acknowledgements

Calgary Study Coordinators were: Krista Carlson, Sana Fakhri, Megan Farris, Quinn Harris, Sarah MacLaughlin, Erica Roberts, and Kristen Simone. Edmonton Study Coordinators were: Natalie Ilkow, Ciara Kallal, and Dr. Amy Speed Andrews. Assistance with information sessions was provided in Calgary by Dr. Brigid Lynch and Fabiola Aparicio-Ting. Calgary Exercise Trainers were: Carrie Anderson, Alia Bhanwani, Shannon Brown, Ashley Cuthbert, Sue Daniel, Julie Gowans, Margo Graham, Erin Korsbrey, Kathleen Kräenbühl, Jessica Morrison, Jason Ng, Nicole Slot, Tania White, and Kaila Wright. Edmonton Exercise Trainers were: Anne Anderson, Lisa Belanger, Jennifer Crawford, Cindy Forbes, Alyssa Hindle, Corey Kuzio, Erin McGowan, Mary Norris, Janet Park, Julianne Symons, Linda Tinhi, Stephanie Voaklander and Lynne Wong. Study recruiters were: Jennie Duke, Jasdeep Hayer, Trisha Kelly, Jasmine Lee, and Lily Mah. Data entry was done by: Sinead Boyle, Barbara Mercer, Carla Quesnel and Trisha Kelly. Data management, including database creation, questionnaire design, data integrity and quality control, was done by: Dr. Steven Szarka, Farit Valievetov, and Wendy Walroth. Qinggang Wang was responsible for the randomization procedures, sample size calculations and some data verification. The late Dr. Robert C. Millikan was a co-investigator on this trial and contributed to the study design and methods.

Availability of data and materials

The datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

Authors’ contributions

DB assisted in data collection, interpretation and wrote the manuscript. YR completed the data analysis and assisted in interpretation and writing of the manuscript. AM assisted in interpretation and writing of the manuscript. CF and KC were responsible for the design and conduct of the study, data collection as well as writing and critical review of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the Health Research Ethics Board of Alberta and all participants consented to participate.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References

1. Friedenreich CM, Neilson HK, Lynch BM. State of the epidemiological evidence on physical activity and cancer prevention. Eur J Cancer. 2010; 46(14):2593–604.
2. Wang M, Wu X, Chai F, Zhang Y, Xiang J. Plasma prolactin and breast cancer risk: a meta-analysis. Sci Rep. 2016;6:25998.
3. Tworoger SS, Sorensen B, Chubak J, et al. Effect of a 12-month randomized clinical trial of exercise on serum prolactin concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2007;16(5):895–9.
4. Reding KW, Lampe JW, Wang CY, et al. A 12-month moderate-intensity exercise intervention does not alter serum prolactin concentrations. Cancer Epidemiol. 2011;35(6):569–73.
5. Friedenreich CM, MacLaughlin S, Neilson HK, et al. Study design and methods for the Breast Cancer and Exercise Trial in Alberta (BETA). BMC Cancer. 2014;14:919.
6. Pollock ML, Foster C, Schmidt D, Hellman C, Linnerud AC, Ward A. Comparative analysis of physiologic responses to three different maximal graded exercise test protocols in healthy women. Am Heart J. 1982;103(3):363–73.
7. Thompson PD, Arena R, Riebe D, Pescatello LS. American College of Sports Medicine’s new preparticipation health screening recommendations from ACSM’s guidelines for exercise testing and prescription, ninth edition. Curr Sports Med Rep. 2013;12(4):215–7.
8. Tanner MJ, Hadlow NC, Wardrop R. Variation of female prolactin levels with menopausal status and phase of menstrual cycle. Aust N Z J Obstet Gynaecol. 2011;51(4):321–4.
9. Friedenreich CM, Neilson HK, O’Reilly R, et al. Effects of a High vs Moderate Volume of Aerobic Exercise on Adiposity Outcomes in Postmenopausal Women: A Randomized Clinical Trial. JAMA Oncol. 2015;1(6):766–76.
10. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev. 2003;24(1):1–27.
11. Tworoger SS, Elashoff RM, Sluss P, Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol. 2007;25(12):1482–8.
12. Chang FE, Dodds WG, Sullivan M, Kim MH, Malarkey WB. The acute effects of exercise on prolactin and growth hormone secretion: comparison between sedentary women and women runners with normal and abnormal menstrual cycles. J Clin Endocrinol Metab. 1986;62(3):351–6.
13. De Cree C. Sex steroid metabolism and menstrual irregularities in the exercising female. A review. Sports Med. 1998;25(6):369–406.
14. Boyden TW, Pamenter RW, Grosso D, Stanforth P, Rotkas T, Willmore JH. Prolactin responses, menstrual cycles, and body composition of women runners. J Clin Endocrinol Metab. 1982;54(4):711–4.